Acadian Asset Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-172,958
| Closed | -$4K | – | 2062 |
|
|
2022
Q4 | $4K | Hold |
172,958
| – | – | ﹤0.01% | 1752 |
|
|
2022
Q3 | $29K | Sell |
172,958
-99,812
| -37% | -$16.7K | ﹤0.01% | 1565 |
|
|
2022
Q2 | $164K | Sell |
272,770
-52,490
| -16% | -$31.6K | ﹤0.01% | 1250 |
|
|
2022
Q1 | $428K | Sell |
325,260
-135
| -0% | -$178 | ﹤0.01% | 1041 |
|
|
2021
Q4 | $847K | Buy |
325,395
+312,845
| +2,493% | +$814K | ﹤0.01% | 868 |
|
|
2021
Q3 | $39K | Buy |
+12,550
| New | +$39K | ﹤0.01% | 1584 |
|
|
2020
Q2 | – | Sell |
-138
| Closed | – | – | 2385 |
|
|
2020
Q1 | $0 | Sell |
138
-13,661
| -99% | – | ﹤0.01% | 1989 |
|
|
2019
Q4 | $84K | Buy |
13,799
+8,860
| +179% | +$53.9K | ﹤0.01% | 1517 |
|
|
2019
Q3 | $21K | Buy |
+4,939
| New | +$21K | ﹤0.01% | 1716 |
|